By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New prostate drug could delay use of chemo

A new option for the early treatment of prostate cancer has been licensed for use in the UK and other European Union countries.

Abiraterone acetate (Zytiga) is the first drug to be licensed for treating the disease stage after hormones but before chemotherapy.

Its use could, therefore, potentially delay the need for cytotoxic chemotherapy.

Specifically the drug has been licensed for use in conjunction with prednisolone, for the treatment of metastatic castration resistant prostate cancer in men who are asymptomatic, or mildly symptomatic, after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Bruce Turner, nurse practitioner at Homerton University Hospital and Barts Health, welcomed the licensing of the new drug.

He said: “The availability of an additional treatment approach that can be used in the urology clinic is an exciting development for nurses, who have long been at the heart of providing care and administering hormonal treatments for prostate cancer patients as part of the multidisciplinary team.”

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!